eXoZymes Inc. (NASDAQ:EXOZ - Get Free Report)'s share price fell 3.2% during trading on Wednesday . The company traded as low as $12.85 and last traded at $13.07. 1,960 shares changed hands during trading, a decline of 41% from the average session volume of 3,338 shares. The stock had previously closed at $13.50.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings restated a "sell (e+)" rating on shares of eXoZymes in a research report on Wednesday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, eXoZymes currently has an average rating of "Sell".
View Our Latest Research Report on EXOZ
eXoZymes Price Performance
The company has a debt-to-equity ratio of 0.01, a current ratio of 6.19 and a quick ratio of 6.19. The business's 50-day moving average price is $11.62 and its two-hundred day moving average price is $11.60.
eXoZymes (NASDAQ:EXOZ - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.28) earnings per share for the quarter.
About eXoZymes
(
Get Free Report)
eXoZymes, Inc is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider eXoZymes, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and eXoZymes wasn't on the list.
While eXoZymes currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
